Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:05:58.485Z.
Calculation as of: 2026-10-06T15:05:58.485Z.
Quote observation: 2026-10-06T14:53:37.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f9d3bab38235a1653807ee573cee89b2588007a5210257548b702658f8274e90
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
BioRestorative Therapies, Inc.
Market Cap
$3.04M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| BioRestorative Therapies, Inc. (BRTX) | $3.04M | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $2.91M | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.17M | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.33M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.32M | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.30M | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.67M | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.51M | N/A |
| Evogene Ltd. (EVGN)vs › | $3.40M | N/A |
| Nuwellis, Inc. (NUWE)vs › | $2.56M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
